BIOCRATES and ALTANA Expand Metabolomics Collaboration
News Apr 06, 2006
Based on successful pilot studies in high-resolution pharmacodynamics, BIOCRATES Life Sciences GmbH and ALTANA Pharma AG signed a collaboration contract comprising joint method development for targeted metabolite profiling as well as further preclinical and clinical studies.
“We are very pleased to gain an innovative pharma partner like ALTANA Pharma in one of our main business areas”, said Armin Graber Ph.D., BIOCRATES’ CEO. “This collaboration will broaden our analytical panel and adapt it to the needs of the pharmaceutical industry.”
The medical focus of the joint projects will be on a better understanding of inflammatory processes in respiratory diseases in view of the development of novel multiparametric biomarkers for drug development and therapy monitoring.
“A targeted and quantitative approach to metabolomics allows to immediately deduce biologically relevant information from the analytical data”, says Klaus Weinberger Ph.D., CSO of BIOCRATES. “Important enzymatic reactions and entire metabolic pathways can now be monitored on a fully standardized basis.”
“Pilot studies in disease model characterization and pharmacodynamics have impressively demonstrated the huge potential of this technology for drug development”, adds Sascha Dammeier Ph.D., Head of Protein Technologies at ALTANA Pharma AG. “We aim at exploiting this potential to obtain additional relevant mode-of-action data in many steps of preclinical and clinical drug development.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE